Klinische Relevanz von Wundverbänden mit TLC-NOSF-Matrix im alltäglichen Management chronischer Wunden – Gepoolte Datenanalyse

Zusammenfassung

Zielsetzung

In mehreren klinischen Studien konnte gezeigt werden, dass verschiedene Wundverbände mit TLC-NOSF-Matrix die Heilung chronischer Wunden unterstützen und kosteneffektiv sind. Anhand einer gepoolten Analyse aus 2 Beobachtungsstudien sollte daher jetzt die Bewertung der klinischen Relevanz von polyabsorbierenden TLC-NOSF (Sucrose-Octasulfat)-Wundverbänden im ambulanten Praxisalltag untersucht werden.

Methoden

Gepoolte Datenanalyse von 2 prospektiven, multizentrischen Beobachtungsstudien aus den Jahren 2017–2018 (N=1.140 Patienten) und 2019–2020 (N=961 Patienten) mit Ulcus cruris (UC), diabetischem Fußulkus (DFU), Dekubitus oder anderen chronischen Wunden zur Evaluation zahlreicher Wundparameter.

Ergebnisse

Unter Anwendung polyabsorbierender Wundverbände mit der TLC-NOSF-Matrix wurde eine kontinuierliche Verbesserung des Wundheilungsprozesses festgestellt, unabhängig von Art bzw. Ätiologie der chronischen Wunden. Nach einer maximalen Beobachtungsdauer von 12 Wochen hatte sich der Zustand der Wunden bei 93,1% der Patienten verbessert. Dabei wurde umso häufiger ein Wundverschluss erzielt, je eher mit der Behandlung begonnen worden war. Bei ≤1 Monat alten Wunden variierte dies zwischen 54,3% (Dekubitus), 55,9% (UC), 61,0% (andere Wunden) und 64,2% (DFU).

Schlussfolgerung

Diese Ergebnisse entsprechen den bisher bekannten Erkenntnissen aus klinischen Studien für TLC-NOSF-Wundverbände und vervollständigen die Evidenzlage bezüglich der guten, die Wundheilung fördernden Eigenschaften, Sicherheit und Akzeptanz unabhängig von den Charakteristika der Patienten und den Wundeigenschaften auch im ambulanten Praxisalltag in Deutschland. Dies unterstützt die Empfehlungen aktueller nationaler und internationaler Leitlinien und Publikationen, Wundverbände mit der TLC-NOSF-Matrix bei nicht infizierten chronischen Wunden mit einer geeigneten Standardversorgung so früh wie möglich in der Behandlung chronischer Wunden bis zu deren Abheilung einzusetzen.

Abstract

Objective

Different wound dressings with TLC-NOSF matrix support the healing of chronic wounds and are cost-effective as shown in various clinical studies. In a pooled analysis of two observational studies, the clinical relevance of polyabsorbent TLC-NOSF (sucrose octasulfate) wound dressings in everyday outpatient practice should therefore now be analysed.

Methods

A pooled data analysis of two prospective, multicentre observational studies from the years 2017–2018 (N=1,140 patients) and 2019–2020 (N=961 patients) with legs ulcers (LU), diabetic foot ulcers (DFU), pressure ulcers (PU) or other types of chronic wounds was conducted to evaluate several wound parameters.

Results

Using polyabsorbent wound dressings with TLC-NOSF matrix, a continuous improvement in the wound healing process was observed, regardless of the type resp. aetiology of the chronic wounds. After a maximum observation period of 12 weeks, the condition of the wounds had improved in 93.1% of patients. Complete wound healing was achieved more frequently, the earlier treatment was initiated: For wounds with a duration of ≤1 month this varied between 54.3% (PU), 55.9% (LU), 61.0% (other wounds) and 64.2% (DFU).

Conclusion

These results are consistent with previously known findings from clinical studies with TLC-NOSF wound dressings and complete the evidence base regarding their good healing properties, safety and acceptance regardless of patient characteristics and wound properties in everyday outpatient practice in Germany. This supports the recommendations of current national and international guidelines and publications to use wound dressings with TLC-NOSF-matrix for non-infected chronic wounds with an appropriate standard of care as early as possible in the treatment of chronic wounds until they have healed.

Schlüsselwörter

UrgoStart Plus - TLC-NOSF-Wundverband - chronische Wunden - Wundverschluss

Keywords

UrgoStart Plus - TLC-NOSF wound dressing - chronic wounds - wound closure

Publikationsverlauf

Artikel online veröffentlicht:
24. April 2025

• Literatur

• 1 Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376: 2367-2375
• 2 Guest JF, Fuller GW, Vowden P. Cohort study evaluating the burden of wounds to the UK's National Health Service in 2017/2018: Update from 2012/2013. BMJ open 2020; 10: e045253 e045253
• 3 Lazaro JL, Izzo V, Meaume S. et al. Elevated levels of matrix metalloproteinases and chronic wound healing: an updated review of clinical evidence. J Wound Care 2016; 25: 277-287
• 4 Armstrong DG, Tan TW, Boulton AJM. et al. Diabetic foot ulcers: A review. JAMA 2023; 330: 62-75
• 5 Armstrong DG, Swerdlow MA, Armstrong AA. et al. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res 2020; 13: 16
• 6 Bui UT, Edwards H, Finlayson K. Identifying risk factors associated with infection in patients with chronic leg ulcers. Int Wound J 2018; 15: 283-290
• 7 Fino P, Di Taranto G, Pierro A. et al. Depression risk among patients with chronic wounds. Eur Rev Med Pharmacol Sci 2019; 23: 4310-4312
• 8 Green J, Jester R, McKinley R. et al. The impact of chronic venous leg ulcers: a systematic review. J Wound Care 2014; 23: 601-612
• 9 Leren L, Johansen E, Eide H. et al. Pain in persons with chronic venous leg ulcers: A systematic review and meta-analysis. Int Wound J 2020; 17: 466-484
• 10 Reinboldt-Jockenhöfer F, Babadagi Z, Hoppe HD. et al. Association of wound genesis on varying aspects of health-related quality of life in patients with different types of chronic wounds: Results of a cross-sectional multicentre study. Int Wound J 2021; 18: 432-439
• 11 Dissemond J, Augustin M, Dietlein M. et al. Sucrose octasulfate-evidence in the treatment of chronic wounds. Hautarzt 2020; 71: 791-801
• 12 Edmonds M, Lázaro-Martínez JL, Alfayate-García JM. et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol 2018; 6: 186-196
• 13 Meaume S, Truchetet F, Cambazard F. et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen 2012; 20: 500-511
• 14 Münter KC, Meaume S, Augustin M. et al. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26: S4-S15
• 15 Schmutz JL, Meaume S, Fays S. et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. Int Wound J 2008; 5: 172-182
• 16 Augustin M, Herberger K, Kroeger K. et al. Cost-effectiveness of treating vascular leg ulcers with UrgoStart and UrgoCell Contact. Int Wound J 2016; 13: 82-87
• 17 Dissemond J, Lützkendorf S, Dietlein M. et al. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care 2020; 29: 350-361
• 18 Lázaro-Martínez JL, Edmonds M, Rayman G. et al. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. J Wound Care 2019; 28: 358-367
• 19 Lobmann R, Augustin M, Lawall H. et al. Cost-effectiveness of TLC-sucrose octasulfate versus control dressings in the treatment of diabetic foot ulcers. J Wound Care 2019; 28: 808-816
• 20 Lobmann R, Grünerbel A, Lawall H. et al. Impact of wound duration on diabetic foot ulcer healing: evaluation of a new sucrose octasulfate wound dressing. J Wound Care 2020; 29: 543-551
• 21 Maunoury F, Oury A, Fortin S. et al. Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France. PloS One 2021; 16: e0245652
• 22 Meaume S, Dompmartin A, Lok C. et al. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomised controlled trial. J Wound Care 2017; 26: 368-379
• 23 National Institute for Health and Care Excellence (NICE). UrgoStart for treating diabetic foot ulcers and leg ulcers. Medical technologies guidance [MTG42]. [published: 31 January 2019, last updated: 4 April 2023] Zugriff am 09. Januar 2024 unter: https://tinyurl.com/6b2k8czb 2023
• 24 Sigal ML, Addala A, Maillard H. et al. Evaluation of TLC-NOSF dressing with poly-absorbent fibres in exuding leg ulcers: two multicentric, single-arm, prospective, open-label clinical trials. J Wound Care 2019; 28: 164-175
• 25 Wen J, Jin X, Al Sayah F. et al. Economic evaluation of sucrose octasulfate dressing for treatment of diabetic foot ulcers in patients with type 2 diabetes. Can J Diabetes 2022; 46: 126-133
• 26 Augustin M, Keuthage W, Lobmann R. et al. Clinical evaluation of UrgoStart Plus dressings in real-life conditions: results of a prospective multicentre study on 961 patients. J Wound Care 2021; 30: 966-978
• 27 Augustin M, Baade K, Herberger K. et al. Use of the WoundQoL instrument in routine practice: Feasibility, validity and development of an implementation tool. Wound Med 2014; 5: 4-8
• 28 Blome C, Baade K, Debus ES. et al. The “Wound-QoL”: a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen 2014; 22: 504-514
• 29 Binder B, Dissemond J, Hämmerle G. et al. Guideline for the treatment of chronic wounds with polyabsorbent TLC-Sucrose Octasulfate wound dressings. WUNDmanagement 2021; 15: 181-190
• 30 Deutsche Gesellschaft für Wundheilung und Wundbehandlung e.V. (DGfW; Hrsg.). Lokaltherapie schwerheilender und/oder chronischer Wunden aufgrund von peripherer arterieller Verschlusskrankheit, Diabetes mellitus oder chronischer venöser Insuffizienz. Version 2.1. Stand: 11.09.2023. AWMF-Register-Nr.: 091/001 Zugriff am 08. Juli 2024 unter: https://register.awmf.org/de/leitlinien/detail/091-001
• 31 Schaper NC, van Netten JJ, Apelqvist J. et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev 2024; 40: e3657